Zacks Small Cap Research on MSN
RADX: RAD 101 phase IIb interim analysis
By John Vandermosten, CFA NASDAQ: RADX RAD 101 Phase IIb Second Interim Data Analysis Approximately three months after the first interim readout from the RAD 101 Phase IIb trial, Radiopharm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results